PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals

: Mr. Mantick has over 25 years of experience in the pharmaceutical and biotech industries. Prior to joining PAREXEL he served as an Executive Director at Abt Bio-Pharma Solutions Inc.where he led the Observational Studies/Registries Business Unit. Previously at Genzyme he was responsible for ongoing management of four global registries for rare diseases. In that capacity h

>: Mr. Mantick has over 25 years of experience in the pharmaceutical and biotech industries. Prior to joining PAREXEL, he served as an Executive Director at Abt Bio-Pharma Solutions, Inc.where he led the Observational Studies/Registries Business Unit. Previously at Genzyme, he was responsible for ongoing management of four global registries for rare diseases. In that capacity, he participated in groundbreaking advancements in the medical treatment of patients and led the registry programs through growth and evolution to meet a wider range of clinical, regulatory, and commercial expectations. Mr. Mantick holds a B.S. degree in Pharmacy from the University of Kentucky and an M.S. degree in Health Policy and Management from the Harvard University School of Public Health.

David Brown, Ph.D., Vice President, Epidemiology: Most recently, Dr. Brown served as Senior Director of Epidemiology at King Pharmaceuticals, which was acquired by Pfizer Inc. Prior to joining King Pharmaceuticals, he held senior positions in epidemiology and global safety surveillance, including serving as epidemiology team leader for oncology and neurosciences at Wyeth Research. Dr. Brown holds a doctorate in epidemiology from the University of Alabama at Birmingham, and earned his Master's degree in public health from Loma Linda University, as well as a Master's degree in cellular and molecular biology from the University of California at Riverside.

Deborah Lubeck, Ph.D.,Vice President, Health Economics and Outcomes Research: Prior to PAREXEL, Dr. Lubeck served as Vice President of Late Phase Services at a major CRO. Previously, she was a member of the research faculty at Stanford University and the University of California, San Francisco. Dr. Lubeck has been involved in outcomes research for 25 years and has coauthored over 160 peer-reviewed publications. Her research has focused on the design and analysis of observation'/>"/>

... Ohio, Nov. 30, 2011 Safecor Health, the market ... they have finalized a one-year extension to their ... repackaging and bar coding services. Under the terms ... continue to provide a comprehensive menu of unit-dose ...

... ATLANTA, Nov. 30, 2011 UCB, a leading biopharmaceutical ... and research, is proud to sponsor several key sets ... Meeting of the American Epilepsy Society (AES) in Baltimore, ... are committed to working toward improving the lives of ...

(Date:3/31/2015)... March 31, 2015 April is Parkinson’s disease ... proud to announce 30 Days, 30 Ways to Make a ... month-long campaign that will offer a new action each day ... of those who battle this disease. , Every ... in April alone nearly 5,000 individuals in this country will ...

(Date:3/31/2015)... Dr. François Blaudeau, the founder of ... a power morcellator lawsuit filed on behalf ... of metastatic leiomyosarcoma, a rare and aggressive form of ... filed by her husband and is currently pending in ... that the power morcellator used during her March 2012 ...

(Date:3/31/2015)... 31, 2015 Beckman Coulter is sponsoring ... Analysis,” with Borries Demeler, which will highlight approaches used ... webinar is free to attend and will be broadcast ... recent years, sophisticated new methods for sedimentation data ... AUC technology in a wide range of technology sectors, ...

(Date:3/31/2015)... The Denver Regional Council of Governments ... an array of public activities which include invitations to ... a Unity Parade and Rally at Denver Union Station ... a national day of advocacy on April 9 to ... , The effort is being led by the American ...

... Jones Graduate School of Business found that despite the 8 ... are not yet wavering in their support of or satisfaction ... of a national sample of U.S. vehicle owners found that ... equally high among Toyota owners and owners of other vehicles, ...

... As many as three tests confirmed Sterillium ... tests according to FDA (Time Kill study ... Antiseptic Drug Products) and one European test ... meets the relevant international efficacy specifications. Sterillium ...

Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...

Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....